Page 204 - Haematologica Vol. 109 - July 2024

ARTICLE - FLT3L promotes osteolysis in multiple myeloma
D. Shin et al.
concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer. 2006;119(7):1728-1731.
18. Yu F, Yu C, Li F, et al. Wnt/b-catenin signaling in cancers and targeted therapies. Signal Transduct Target Ther. 2021;6(1):307.
19. Steiner N, Hajek R, Sevcikova S, et al. High levels of FLT3-ligand in bone marrow and peripheral blood of patients with advanced multiple myeloma. PLoS One. 2017;12(7):e0181487.
20. Kokonozaki M, Kanellou P, Pappa CA, et al. Serum levels of soluble FLT3 ligand in patients with active multiple myeloma constitute marker of bone marrow plasma cell proliferative activity. Crit Rev Oncog. 2017;22(3-4):255-262.
21. Anandasabapathy N, Breton G, Hurley A, et al. Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant. 2015;50(7):924-930.
22. Uckun FM. Overcoming the immunosuppressive tumor microenvironment in multiple myeloma. Cancers (Basel). 2021;13(9):2018.
23. Hayakawa F, Sugimoto K, Harada Y, et al. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J. 2013;3(11):e166.
24. Chérel M, Gouard S, Gaschet J, et al. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J Nucl Med. 2013;54(9):1597-1604.
25. Cho H. Diagnosis and management of monoclonal gammopathy of clinical significance. Blood Res. 2022;57(S1):20-26.
26. Zheng R, Levis M, Piloto O, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004;103(1):267-274.
27. Zhou J, Bi C, Janakakumara JV, et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood. 2009;113(17):4052-4062.
28. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334(8):488-493.
29. Laouar Y, Welte T, Fu XY, Flavell RA. STAT3 is required for Flt3L- dependent dendritic cell differentiation. Immunity. 2003;19(6):903-912.
30. Chauvistré H, Küstermann C, Rehage N, et al. Dendritic cell development requires histone deacetylase activity. Eur J Immunol. 2014;44(8):2478-2488.
31. Kamburov A, Wierling C, Lehrach H, Herwig R. ConsensusPathDB--a database for integrating human functional interaction networks. Nucleic Acids Res. 2009;37(Database issue):D623-628.
32. Gau YC, Yeh TJ, Hsu CM, Hsiao SY, Hsiao HH. Pathogenesis and treatment of myeloma-related bone disease. Int J Mol Sci. 2022;23(6):3112.
33. Liu Z, Liu H, Li Y, et al. Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma. Int J Mol Med. 2020;45(4):1112-1120.
34. Liu H, He J, Yang J. Tumor cell p38 MAPK: a trigger of cancer bone osteolysis. Cancer Cell Microenviron. 2015;2(1):e464.
35. Beiter K, Hiendlmeyer E, Brabletz T, et al. beta-Catenin regulates the expression of tenascin-C in human colorectal tumors. Oncogene. 2005;24(55):8200-8204.
36. Zhou R, Yuan Z, Liu J, Liu J. Calcitonin gene-related peptide promotes the expression of osteoblastic genes and activates the WNT signal transduction pathway in bone marrow stromal stem cells. Mol Med Rep. 2016;13(6):4689-4696.
37. Bonnet N, Brun J, Rousseau JC, Duong LT, Ferrari SL. Cathepsin K controls cortical bone formation by degrading periostin. J Bone Miner Res. 2017;32(7):1432-1441.
38. Zhu B, Xue F, Li G, Zhang C. CRYAB promotes osteogenic differentiation of human bone marrow stem cells via stabilizing b-catenin and promoting the Wnt signalling. Cell Prolif. 2020;53(1):e12709.
39. Chng WJ, Kumar S, Vanwier S, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007;67(7):2982-2989.
40. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98(7):2229-2238.
41. Weinhold N, Kirn D, Seckinger A, et al. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2016;101(3):e116-119.
42. Chretien ML, Corre J, Lauwers-Cances V, et al. Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? Blood. 2015;126(25):2713-2719.
43. Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008;113(7):1588-1595.
44. Raje N, Woo SB, Hande K, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008;14(8):2387-2395.
45. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011;305(8):783-789.
46. Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double- dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018;19(3):370-381.
47. Himelstein AL, Foster JC, Khatcheressian JL, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA. 2017;317(1):48-58.
48. Gebru MT, Wang HG. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):155.
49. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr. Dkk1- induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone. 2008;42(4):669-680.
50. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-2028.
Haematologica | 109 July 2024
2218